Clinical Trial Update: Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating autologous T cells engineered to target PSMA for men with metastatic castration-resistant prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Autologous PSMA-targeted T cells

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Prostate Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING